AB Science (AB.PA): Final Results Of Phase 3 Mastocytosis Study Expected By End Of 2014
11/12/2013 1:36:49 PM
PARIS, Nov. 12, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), following the press release from November 11th that announced the phase 3 study's success in the futility analysis, further specifies important points concerning availability of phase 3 data, number of patients treatable and sustainability of response generated by masitinib observed in phase 2.
Help employers find you! Check out all the jobs and post your resume.
comments powered by